Read the full article here.
This content was originally published by the new yorker business. Original publishers retain all rights. It appears here for a limited time before automated archiving. By the new yorker business
Jerome Groopman writes on the disappointing findings of new clinical studies of the drug cocktail hydroxychloroquine and azithromycin, which has been touted by President Trump and approved for emergency use by the F.D.A., in treating the coronavirus.